Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mapping thyroid cancer: spanish hospitals pool records to chart tumor types and outcomes

NCT ID NCT03765333

Knowledge-focused Sponsor: Grupo Espanol de Tumores Neuroendocrinos Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 22, 2026 · Last updated Sep 23, 2026 · Updated 1 time

Summary

Researchers in Spain are building a registry of adults diagnosed with differentiated, medullary, or anaplastic thyroid cancer. The study reviews existing medical records from oncology services at participating centers to describe tumor characteristics, stage at diagnosis, and how patients respond to treatment. It also tracks whether tumors carry a BRAF mutation. The goal is to understand the range of thyroid cancers seen in routine practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the registry succeeds, it could give doctors a clearer picture of how different thyroid cancers behave across Spain, which may help guide future treatment decisions.
What could go wrong
This is a small, retrospective study that only reviews existing records, so it cannot prove what causes thyroid cancer or which treatment works best. Its findings may not apply to patients outside the participating centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2019

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients ≥ 18 years visited in the oncology services of the participating centers that have a diagnosis of primary cancer located in the thyroid gland.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients older than 18 years with diagnosis of differentiated, medullary or anaplastic thyroid cancer confirmed by histopathology. * Patients who agree to participate and are able to understand the information sheet and sign the informed consent Exclusion Criteria: * Patients under 18 years of age. * Patients with other types of thyroid cancer or whose histopathological diagnosis has not been confirmed. * Patients who do not have the relevant basic information to be included in the study, according to the criteria of the principal investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anaplastic thyroid cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma medullary thyroid gland carcinoma thyroid cancer thyroid gland undifferentiated (anaplastic) carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Universitari Vall d'Hebron

    RECRUITING

    Barcelona, Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.